La Roche-Posay Effaclar Acne Kit Recalled Over Benzene Contamination

L’Oreal USA has voluntarily recalled all lots of the La Roche-Posay Effaclar Dermatological Acne System following the detection of trace amounts of benzene in a specific batch of the product. Though the contaminant was confirmed only in lot MYX46W, the company has recalled all lots of the Effaclar Duo Dual Action Acne Treatment out of an abundance of caution. The recall affects a 3-step acne treatment kit that includes a Medicated Gel Cleanser, Clarifying Solution, and the Dual Action Acne Treatment, which contains benzoyl peroxide at concentrations of 0.5% and 5.5%. A total of 14 460 units were distributed nationwide across the US.

This recall has been classified as a Class II event by the US Food and Drug Administration (FDA), indicating that exposure to the product may cause temporary or medically reversible adverse health consequences, but the probability of serious adverse health consequences is remote. The recall (number D-0418-2025) was initiated on March 5, 2025, with formal classification by the FDA on May 9, 2025. Consignees were notified through direct letters, and no public press release has been issued as of this report. The recall remains ongoing.

The Effaclar Dermatological Acne System is commonly recommended for patients managing mild to moderate acne. Its active ingredient, benzoyl peroxide, is widely used for its antibacterial properties in treating acne vulgaris by reducing Propionibacterium acnes on the skin and promoting skin turnover. Pharmacists should be aware of the recall when dispensing or recommending over-the-counter acne regimens and advise patients accordingly on safer alternatives if needed.